GaiaCell develops advanced cell and gene therapy platforms with a clear translational focus, aimed at clinical applicability, industrial collaboration, and long-term value creation.
Our development programs are based on in-house expertise, infrastructure, and experience in the development, manufacturing, and clinical implementation of cell therapies.
GaiaCell’s research and development activities are designed as a bridge between research and clinical application. Special emphasis is placed on translational development with a clear clinical orientation, control of key technological components, development of solutions that are logistically, temporally, and economically feasible, and collaboration with industrial and clinical partners.
Below we present three core development platforms that form the backbone of our R&D portfolio.
Development of CAR-T cell therapies with a focus on simplifying manufacturing, improving patient accessibility, and increasing control over key technological elements.
Development of therapies based on tumor-infiltrating lymphocytes (TILs) as a personalized immunotherapeutic approach for solid tumors.
Development of exosome platforms as a cell-free therapeutic and delivery system with potential for broader clinical application.
GaiaCell’s development platforms are designed for collaboration with:
We are open to various forms of collaboration, including development partnerships, technology licensing, and strategic investments.